Drug Profile
Phenylalanine ammonia lyase encapsulated erythrocytes - Quince Therapeutics
Alternative Names: Ery-PAL; Erythrocyte encapsulated PAL - Quince Therapeutics; PAL erythrocyte encapsulated - Quince Therapeutics; Phenylalanine ammonia lyase erythrocyte encapsulated - Quince TherapeuticsLatest Information Update: 25 Oct 2023
Price :
$50
*
At a glance
- Originator EryDel
- Developer Quince Therapeutics; University of Rome; University of Urbino
- Class Ammonia lyases; Enzymes; Recombinant proteins
- Mechanism of Action Phenylalanine ammonia lyase replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Phenylketonuria
Most Recent Events
- 20 Oct 2023 EryDel has been acquired and merged into Quince Therapeutics
- 03 Feb 2023 Phenylalanine ammonia lyase encapsulated erythrocytes is still in preclinical studies for Phenylketonuria in Italy
- 28 Feb 2022 No recent reports of development identified for preclinical development in Phenylketonuria in Italy (Intracoronary, Injection)